Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basem M William

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Cancers|February 9, 2021
Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationNidhi Sharma, Qiuhong Zhao, Bin Ni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
Hematology (Amsterdam, Netherlands)|January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology|July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
British Journal of Haematology|March 9, 2016
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomesAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2020
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood TransplantScott R Solomon, Andrew St Martin, Mei-Jie Zhang, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Cancers|February 9, 2021
Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationNidhi Sharma, Qiuhong Zhao, Bin Ni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
Hematology (Amsterdam, Netherlands)|January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology|July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
British Journal of Haematology|March 9, 2016
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomesAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2020
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood TransplantScott R Solomon, Andrew St Martin, Mei-Jie Zhang, et al.
Pageof 6